(Sharecast News) - Drugmaker AstraZeneca said on Monday that positive high-level results from a new trial of its Enhertu breast cancer drug had demonstrating a "statistically significant and clinically meaningful improvement" in progression-free survival.
AstraZeneca stated the DESTINY-Breast02 Phase III trial on Enhertu, jointly developed and commercialised with Daiichi Sankyo, also met the key secondary endpoint of improved overall survival.
The FTSE 100-listed firm said the trial evaluated a similar later-line patient population as its previous single-arm DESTINY-Breast01 Phase II trial, which was the basis for initial approvals in advanced HER2-positive metastatic breast cancer.
AZN added that the safety profile of Enhertu in DESTINY-Breast02 was consistent with previous Phase III clinical trials, with no new safety concerns identified.
Executive Vice President of oncology Susan Galbraith said: "The DESTINY-Breast02 trial results in this patient population with advanced disease confirm the efficacy and safety profile seen in DESTINY-Breast01 and are consistent with the results seen across our broader clinical programme in HER2-positive metastatic breast cancer. These data further strengthen our confidence in Enhertu and reinforce its potential to transform patient outcomes across multiple treatment settings."
Reporting by Iain Gilbert at Sharecast.com
Astrazeneca (AZN)
